Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants

Polymers Strive for Accuracy: From Sequence-Defined Polymers to mRNA Vaccines against COVID-19 and Polymers in Nucleic Acid Therapeutics

Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Vaccines, Free Full-Text

Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants – ScienceOpen

Vaccines, Free Full-Text

Omicron-specific booster may not be needed, U.S. monkey study finds

Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2

Frontiers Viral vector and nucleic acid vaccines against COVID-19: A narrative review

Rational prediction of immunogenicity clustering through cross‐reactivity analysis of thirteen SARS‐CoV‐2 variants - Liang - 2024 - Journal of Medical Virology - Wiley Online Library